Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

The National Institutes of Health (NIH) is continuing its grant-canceling spree, allegedly targeting dozens of research ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The AI-focused company is handing over $200 million as an upfront payment, as well as ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

Eye surgery specialist BVI Medical announced this week it has raised $1 billion in new financing as it looks to boost its global intraocular lens business with “several new product launch | BVI said ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...